Abstract
A critical period is a developmental epoch during which the nervous system is expressly sensitive to specific environmental stimuli that are required for proper circuit organization and learning. Mechanistic characterization of critical periods has revealed an important role for exuberant brain plasticity during early development, and for constraints that are imposed on these mechanisms as the brain matures1. In disease states, closure of critical periods limits the ability of the brain to adapt even when optimal conditions are restored. Thus, identification of manipulations that reopen critical periods has been a priority for translational neuroscience2. Here we provide evidence that developmental regulation of oxytocin-mediated synaptic plasticity (long-term depression) in the nucleus accumbens establishes a critical period for social reward learning. Furthermore, we show that a single dose of (+/−)-3,4-methylendioxymethamphetamine (MDMA) reopens the critical period for social reward learning and leads to a metaplastic upregulation of oxytocin-dependent long-term depression. MDMA-induced reopening of this critical period requires activation of oxytocin receptors in the nucleus accumbens, and is recapitulated by stimulation of oxytocin terminals in the nucleus accumbens. These findings have important implications for understanding the pathogenesis of neurodevelopmental diseases that are characterized by social impairments and of disorders that respond to social influence or are the result of social injury3.

Data availability
The pAAV-CAG-FonChronos-TdTomato construct has been deposited on Addgene (accession number 105834). Oxytocin-2A-Flp optimized knock-in mice, and data sets are available from the corresponding author upon request.

Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1.
Hübener, M. & Bonhoeffer, T. Neuronal plasticity: beyond the critical period. Cell 159, 727–737 (2014).

2.
Patton, M. H., Blundon, J. A. & Zakharenko, S. S. Rejuvenation of plasticity in the brain: opening the critical period. Curr. Opin. Neurobiol. 54, 83–89 (2019).

3.
Yazar-Klosinski, B. B. & Mithoefer, M. C. Potential psychiatric uses for MDMA. Clin. Pharmacol. Ther. 101, 194–196 (2017).

4.
Dölen, G., Darvishzadeh, A., Huang, K. W. & Malenka, R. C. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 501, 179–184 (2013).

5.
McEwen, B. B. Brain-fluid barriers: relevance for theoretical controversies regarding vasopressin and oxytocin memory research. Adv. Pharmacol. 50, 531–592, 655–708 (2004).

6.
Lee, M. R. et al. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay. Mol. Psychiatry 23, 115–122 (2018).

7.
Thompson, M. R., Callaghan, P. D., Hunt, G. E., Cornish, J. L. & McGregor, I. S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146, 509–514 (2007).

8.
Hunt, G. E., McGregor, I. S., Cornish, J. L. & Callaghan, P. D. MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res. Bull. 86, 65–73 (2011).

9.
Forsling, M. L. et al. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br. J. Pharmacol. 135, 649–656 (2002).

10.
Shulgin, A. A. T. & Nichols, D. E. Characterization of three new psychotomimetics. Psychopharmacol. Hallucinog. 2, 74–83 (1978).

11.
Rudnick, G. & Wall, S. C. The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA 89, 1817–1821 (1992).

12.
Field, J. R., Henry, L. K. & Blakely, R. D. Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine. J. Biol. Chem. 285, 11270–11280 (2010).

13.
Edsinger, E. & Dölen, G. A conserved role for serotonergic neurotransmission in mediating social behaviour in octopus. Curr. Biol. 28, 3136–3142.e4 (2018).

14.
Simmler, L. D. et al. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 168, 458–470 (2013).

15.
Jørgensen, H., Riis, M., Knigge, U., Kjaer, A. & Warberg, J. Serotonin receptors involved in vasopressin and oxytocin secretion. J. Neuroendocrinol. 15, 242–249 (2003).

16.
Trigo, J. M. et al. 3,4-Methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry 62, 669–679 (2007).

17.
Abraham, W. C. & Bear, M. F. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 19, 126–130 (1996).

18.
Klapoetke, N. C. et al. Independent optical excitation of distinct neural populations. Nat. Methods 11, 338–346 (2014).

19.
Blakemore, S.-J. & Mills, K. L. Is adolescence a sensitive period for sociocultural processing? Annu. Rev. Psychol. 65, 187–207 (2014).

20.
Nelson, E. E., Jarcho, J. M. & Guyer, A. E. Social re-orientation and brain development: an expanded and updated view. Dev. Cogn. Neurosci. 17, 118–127 (2016).

21.
Pedersen, C. A. Biological aspects of social bonding and the roots of human violence. Ann. NY Acad. Sci. 1036, 106–127 (2004).

22.
Leung, R. K., Toumbourou, J. W. & Hemphill, S. A. The effect of peer influence and selection processes on adolescent alcohol use: a systematic review of longitudinal studies. Health Psychol. Rev. 8, 426–457 (2014).

23.
Nicolaisen, M. & Thorsen, K. Who are lonely? Loneliness in different age groups (18–81 years old), using two measures of loneliness. Int. J. Aging Hum. Dev. 78, 229–257 (2014).

24.
Shapiro, L. E. & Insel, T. R. Ontogeny of oxytocin receptors in rat forebrain: a quantitative study. Synapse 4, 259–266 (1989).

25.
Lüscher, C. & Malenka, R. C. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 69, 650–663 (2011).

26.
Nair, S. G. & Gudelsky, G. A. 3,4-Methylenedioxymethamphetamine (MDMA) enhances the release of acetylcholine by 5-HT4 and D1 receptor mechanisms in the rat prefrontal cortex. Synapse 58, 229–235 (2005).

27.
Hagena, H. & Manahan-Vaughan, D. The serotonergic 5-HT4 receptor: A unique modulator of hippocampal synaptic information processing and cognition. Neurobiol. Learn. Mem. 138, 145–153 (2017).

28.
Melroy-Greif, W. E., Stitzel, J. A. & Ehringer, M. A. Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use. Genes Brain Behav. 15, 89–107 (2016).

29.
Mithoefer, M. C. et al. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5, 486–497 (2018).

30.
Young, M. B. et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl.) 234, 2883–2895 (2017).

31.
Wu, Z. et al. An obligate role of oxytocin neurons in diet-induced energy expenditure. PLoS One 7, e45167 (2012).

32.
Furler, S., Paterna, J. C., Weibel, M. & Büeler, H. Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons. Gene Ther. 8, 864–873 (2001).

33.
Chan, H. Y. et al. Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines. PLoS One 6, e28885 (2011).

34.
Douglas, L. A., Varlinskaya, E. I. & Spear, L. P. Rewarding properties of social interactions in adolescent and adult male and female rats: impact of social versus isolate housing of subjects and partners. Dev. Psychobiol. 45, 153–162 (2004).

35.
Panksepp, J. B. & Lahvis, G. P. Social reward among juvenile mice. Genes Brain Behav. 6, 661–671 (2007).

36.
Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 11, 490–502 (2010).

37.
Mathur, B. N., Capik, N. A., Alvarez, V. A. & Lovinger, D. M. Serotonin induces long-term depression at corticostriatal synapses. J. Neurosci. 31, 7402–7411 (2011).

38.
Whitnall, M. H., Key, S., Ben-Barak, Y., Ozato, K. & Gainer, H. Neurophysin in the hypothalamo-neurohypophysial system. II. Immunocytochemical studies of the ontogeny of oxytocinergic and vasopressinergic neurons. J. Neurosci. 5, 98–109 (1985).

39.
Ben-Barak, Y., Russell, J. T., Whitnall, M. H., Ozato, K. & Gainer, H. Neurophysin in the hypothalamo-neurohypophysial system. I. Production and characterization of monoclonal antibodies. J. Neurosci. 5, 81–97 (1985).

40.
Dölen, G. Oxytocin: parallel processing in the social brain? J. Neuroendocrinol. 27, 516–535 (2015).